Enlivex Therapeutics financials at a glance

+ Portfolio

The revenue of Enlivex Therapeutics is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -1.56 Dollars per share in 2023, which was 108.64 lower than 2021. And about -0.00019 billion Dollars are reported as free cash flow in the financials of Enlivex Therapeutics 2023. No dividends were paid to the shareholders of the Enlivex Therapeutics stock NasdaqCM:ENLV in the financial year 2023.

$0.00M

Revenue

$-1.69

Earnings Per Share

0.00%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-1.69

Gross Margin %

0.00

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021	2020	2019	2018
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-1.47	$-1.69	$-0.81	$-0.90	$-1.11	$-1.40
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0
Sha.	Shares	N/AM	18.42M	18.37M	18.31M	13.43M	3.51M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$-7.04M	$0.00M
FCF	Free Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$-7.23M	$0.00M
FCFS	Free Cash Flow Per Share	$-1.40	$-1.74	$-1.07	$-0.91	$-0.84	$-1.03

Enlivex Therapeutics financials at a glance

Financials

Discover